The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial

The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial

PurposeThis multicenter, open-label, phase Ib/II study aimed to assess the efficacy and safety of cadonilimab, a humanized, tetravalent, bispecific antibody plus lenvatinib in first-line treatment of advanced hepatocellular carcinoma (aHCC).MethodsPatients with histologically confirmed aHCC were inc...

Full description

Bibliographic Details
Main Authors:	Qian Qiao, Chun Han, Sisi Ye, Juan Li, Guoliang Shao, Yuxian Bai, Aibing Xu, Meili Sun, Wei Wang, Jian Wu, Ming Huang, Lijie Song, Luke Huang, Ting Liu, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Li Bai
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-10-01
Series:	Frontiers in Immunology
Subjects:	cadonilimab lenvatinib BsA bi-specific antibody hepatocellular carcinoma HCC
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1238667/full

Similar Items

Infusion-Related Reactions Induced by Cadonilimab (PD-1/CTLA-4 Bispecific Antibody): Seven Case Reports
by: Weiting Liang, et al.
Published: (2024-02-01)

Case Report: Cadonilimab-related toxic epidermal necrolysis-like reactions successfully treated with supplemental Adalimumab
by: Peng-Yu Chen, et al.
Published: (2023-08-01)

Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report
by: Jieqiong Peng, et al.
Published: (2022-12-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Tumor lenvatinib addiction and withdrawal rebound response in patients with advanced endometrial cancer
by: Clarissa Lam, et al.
Published: (2023-10-01)

Idarubicin‐Loaded DEB‐TACE plus Lenvatinib versus Lenvatinib for patients with advanced hepatocellular carcinoma: A propensity score‐matching analysis
by: Wenzhe Fan, et al.
Published: (2023-01-01)

Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
by: Keisuke Koroki, et al.
Published: (2021-04-01)

YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS
by: Jun Guo, et al.
Published: (2021-10-01)

Thrombotic microangiopathy associated with lenvatinib therapy
by: Macarena Contreras Angulo, et al.
Published: (2023-04-01)

Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
by: Yun Zhu, et al.
Published: (2021-09-01)

Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
by: Burgio V, et al.
Published: (2021-12-01)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
by: Jonathan T. Hunt, et al.
Published: (2021-08-01)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
by: Yanjun Cui, et al.
Published: (2022-08-01)

Incidence and risk of hypertension with lenvatinib in treatment of solid tumors: An updated systematic review and meta‐analysis
by: Hongxiao Wu, et al.
Published: (2022-06-01)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
by: Qi Li, et al.
Published: (2022-02-01)

Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia
by: Ai Kuwahara, et al.
Published: (2020-08-01)

HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study
by: Xu Chang, et al.
Published: (2024-04-01)

Application and Resistance Mechanisms of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
by: Tao M, et al.
Published: (2023-07-01)

Complete response to the combination of Lenvatinib and Pembrolizumab in an advanced hepatocellular carcinoma patient: a case report
by: Zhaonan Liu, et al.
Published: (2019-11-01)

The multiple‐kinase inhibitor lenvatinib inhibits the proliferation of acute myeloid leukemia cells
by: Fan Feng, et al.
Published: (2019-09-01)

Impact of Local Liver Irradiation Concurrent Versus Sequential with Lenvatinib on Pharmacokinetics and Biodistribution
by: Tung-Hu Tsai, et al.
Published: (2021-03-01)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
by: Matthew Man Pok Lee, et al.
Published: (2023-09-01)

Novel insights into post-marketing adverse events associated with lenvatinib: A comprehensive analysis utilizing the FAERS database
by: Zhe Yu, et al.
Published: (2024-03-01)

Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study
by: Yen-Yang Chen, et al.
Published: (2021-09-01)

Bowel Perforation in a Patient with Hepatocellular Carcinoma during Lenvatinib Treatment
by: Ken Mizokami, et al.
Published: (2022-08-01)

Efficacy of lenvatinib versus sorafenib in the primary treatment of advanced hepatocellular carcinoma: A meta‐analysis
by: Vikash Jaiswal, et al.
Published: (2023-12-01)

Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine‐refractory differentiated thyroid cancer
by: Miguel‐Ángel Berciano‐Guerrero
Published: (2022-10-01)

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
by: Xiaozhun Huang, et al.
Published: (2021-11-01)

Outcomes of Patients with Advanced Hepatocellular Carcinoma Receiving Lenvatinib following Immunotherapy: A Real World Evidence Study
by: Mathias E. Palmer, et al.
Published: (2023-10-01)

Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy
by: Hiroshi Shintani, et al.
Published: (2021-06-01)

The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
by: Jie Zhu, et al.
Published: (2021-11-01)

The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors
by: Wei Sun, et al.
Published: (2024-04-01)

Efficacy of Lenvatinib and Sorafenib in the Real-World First-Line Treatment of Advanced-Stage Hepatocellular Carcinoma in a Taiwanese Population
by: Shou-Wu Lee, et al.
Published: (2022-03-01)

Endobronchial metastasis of hepatocellular carcinoma treated with Lenvatinib: A case report
by: Shota Takei, et al.
Published: (2023-09-01)

A bibliometric study on the utilization of lenvatinib in hepatocellular carcinoma (2014–2022)
by: Cong-Cong Wang, et al.
Published: (2023-06-01)

A Case of Unresectable Combined Hepatocellular-Cholangiocarcinoma Successfully Treated with Lenvatinib
by: Takahiro Osuga, et al.
Published: (2022-03-01)

Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma
by: João Roque, et al.
Published: (2023-04-01)

Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis
by: Dongmei Huang, et al.
Published: (2022-06-01)

Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma
by: Yu-Ju Tseng, et al.
Published: (2022-12-01)

Lenvatinib resistance mechanism and potential ways to conquer
by: Wentao Bo, et al.
Published: (2023-04-01)